DK1162982T3 - Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning - Google Patents

Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning

Info

Publication number
DK1162982T3
DK1162982T3 DK00910993T DK00910993T DK1162982T3 DK 1162982 T3 DK1162982 T3 DK 1162982T3 DK 00910993 T DK00910993 T DK 00910993T DK 00910993 T DK00910993 T DK 00910993T DK 1162982 T3 DK1162982 T3 DK 1162982T3
Authority
DK
Denmark
Prior art keywords
drug
prepare
stabilized oligonucleotides
antitumoral effect
oligonucleotides
Prior art date
Application number
DK00910993T
Other languages
Danish (da)
English (en)
Inventor
Antoine Carpentier
Original Assignee
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK1162982T3 publication Critical patent/DK1162982T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00910993T 1999-03-19 2000-03-17 Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning DK1162982T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9903433A FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
PCT/FR2000/000676 WO2000056342A2 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale

Publications (1)

Publication Number Publication Date
DK1162982T3 true DK1162982T3 (da) 2005-06-13

Family

ID=9543401

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00910993T DK1162982T3 (da) 1999-03-19 2000-03-17 Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning

Country Status (12)

Country Link
US (2) US7700569B1 (enExample)
EP (1) EP1162982B9 (enExample)
JP (1) JP2002539265A (enExample)
AT (1) ATE288759T1 (enExample)
AU (1) AU3300600A (enExample)
CA (1) CA2371990A1 (enExample)
DE (1) DE60018050T2 (enExample)
DK (1) DK1162982T3 (enExample)
ES (1) ES2235839T3 (enExample)
FR (1) FR2790955B1 (enExample)
PT (1) PT1162982E (enExample)
WO (1) WO2000056342A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AU783344B2 (en) 1999-02-17 2005-10-20 Csl Limited Immunogenic complexes and methods relating thereto
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
AU2004280143A1 (en) * 2003-10-11 2005-04-21 Tekmira Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
AU2005266225A1 (en) * 2004-06-25 2006-02-02 Centre National De La Recherche Scientifique Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle
EP1649859A1 (fr) * 2004-10-22 2006-04-26 Institut Gustave Roussy Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
SG160336A1 (en) 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
HRP20150759T1 (hr) 2007-05-11 2015-08-14 Adynxx, Inc. Ekspresija gena i bolovi
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US20130210896A1 (en) * 2011-11-09 2013-08-15 City Of Hope Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
BR112017002629A2 (pt) 2014-08-15 2018-02-20 Adynxx, Inc. decoys de oligonucleotídeo para o tratamento de dor
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
US12377142B2 (en) 2018-03-07 2025-08-05 Transgene Recombinant pseudocowpoxvirus
AU2019412516A1 (en) 2018-12-28 2021-07-15 Transgene M2-defective poxvirus
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
JPH04352724A (ja) * 1990-07-27 1992-12-07 Mitsui Toatsu Chem Inc 免疫調節型治療剤
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1993005182A1 (en) 1991-09-05 1993-03-18 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
WO1994025588A2 (en) 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
DE69433520T2 (de) * 1993-07-10 2004-11-11 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-nukleinsäure enthaltende pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zelltod, und zur behandlung von neoplasmen
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
EP0722342B1 (en) * 1993-09-20 2004-12-29 The Trustees Of The University Of Pennsylvania REGULATION OF bcl-2 GENE EXPRESSION
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
CA2256305A1 (en) 1996-05-22 1997-11-27 Mcgill University Specific inhibitors of dna methyltransferase enzyme
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US5965420A (en) * 1997-03-05 1999-10-12 Smithkline Beecham Corporation Human protein kinases hYAK3
ATE432348T1 (de) * 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
WO1999012027A1 (en) 1997-08-29 1999-03-11 The Regents Of The University Of California Modulators of dna cytosine-5 methyltransferase and methods for use thereof
DE69837094T2 (de) * 1997-09-05 2007-08-30 The Regents Of The University Of California, Oakland Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6060310A (en) * 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6020475A (en) 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
EP1067956B1 (en) * 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6166239A (en) 1998-09-04 2000-12-26 Isis Pharmaceuticals, Inc. Oligonucleotide protecting groups
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
US6069243A (en) 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
WO2000021556A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
JP2002542015A (ja) 1999-04-19 2002-12-10 エンゲルハード・コーポレーシヨン セリアと白金族金属を含んで成る触媒組成物
WO2001051061A1 (en) * 2000-01-14 2001-07-19 Intrabiotics Pharmaceuticals, Inc. Derivatives of polyene macrolides and preparation and use thereof

Also Published As

Publication number Publication date
EP1162982B9 (fr) 2005-07-06
ATE288759T1 (de) 2005-02-15
FR2790955A1 (fr) 2000-09-22
EP1162982A2 (fr) 2001-12-19
JP2002539265A (ja) 2002-11-19
WO2000056342A2 (fr) 2000-09-28
EP1162982B1 (fr) 2005-02-09
PT1162982E (pt) 2005-05-31
AU3300600A (en) 2000-10-09
CA2371990A1 (fr) 2000-09-28
US20020192184A1 (en) 2002-12-19
ES2235839T3 (es) 2005-07-16
DE60018050D1 (de) 2005-03-17
WO2000056342A3 (fr) 2001-07-26
US7700569B1 (en) 2010-04-20
DE60018050T2 (de) 2006-02-23
US7108844B2 (en) 2006-09-19
FR2790955B1 (fr) 2003-01-17

Similar Documents

Publication Publication Date Title
DK1162982T3 (da) Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
DE60138709D1 (de) Analoge der barbitursäure als therapeutische wirkstoffe
SE0001899D0 (sv) New compounds
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
HU9501623D0 (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) as an antidepressant drug
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
IT1318667B1 (it) Medicamento antinfiammatorio.
ATE284878T1 (de) Pharmazeutische verbindungen mit serotonin rezeptor aktivität
DE60036199D1 (de) Proteaseresistente flint-analoge
BR0209138A (pt) Utilização de derivados de piridoindolona para a preparação de medicamentos
DE60207215D1 (de) Arzneiformen zur behandlung von krankheiten, die auf aktivierung des ppar-gamma-rezeptors ansprechen
AR013538A1 (es) Nuevos mitogenos especificos de osteoblastos, metodos para prepararlos y drogas que contienen tales compuestos
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
ATE227997T1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
TH54252A3 (th) อนุพันธ์ไพราโซล ที่ถูกเข้าแทนที่ตัวใหม่